ALFA USA News
Straight from the SEC filing
Every SEC filing by Vir Biotechnology, Inc. that we have reported, newest first. Each story links the original filing.
Reference market data from a third-party provider, as of the most recent story (14 Oct 2026). Not a valuation or a recommendation.
Down 1.4% over the last month ($10.77 on 14 Sep → $10.61 on 13 Oct). Daily closing prices. Source: Yahoo Finance.
| 14 Sep | $10.77 |
|---|---|
| 15 Sep | $10.44 |
| 16 Sep | $10.52 |
| 17 Sep | $10.92 |
| 18 Sep | $10.60 |
| 21 Sep | $10.88 |
| 22 Sep | $11.50 |
| 23 Sep | $11.09 |
| 24 Sep | $10.72 |
| 25 Sep | $10.66 |
| 28 Sep | $10.51 |
| 29 Sep | $10.65 |
| 30 Sep | $11.18 |
| 1 Oct | $11.29 |
| 2 Oct | $11.17 |
| 5 Oct | $11.78 |
| 6 Oct | $11.60 |
| 7 Oct | $11.52 |
| 8 Oct | $11.12 |
| 9 Oct | $11.70 |
| 12 Oct | $11.30 |
| 13 Oct | $10.61 |
Vir Biotechnology (VIR) secures a $1.875 billion collaboration with Gilead Sciences to develop three novel T-cell engagers for solid tumors using AI technology.
Vir Biotechnology receives FDA Fast Track designation for VIR-5500 in prostate cancer. Phase 3 trials set for 2027 as company maintains $1B in cash reserves.
Track Vir Biotechnology, Inc. live
Get the next Vir Biotechnology, Inc. SEC filing seconds after it lands.
